View Older Stories View More Recent Stories

Jun 5, 2023 11:04AM Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
Jun 3, 2023 08:00PM Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
Jun 1, 2023 09:00AM New Research Shows That Hiring Is Harder Than Ever: Time to Hire Increasing Significantly for Almost All Roles
Jun 1, 2023 08:30AM RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial
May 20, 2023 02:54PM Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies
May 16, 2023 08:35AM Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
May 4, 2023 08:00AM Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (fecal microbiota, live – jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open F
Apr 30, 2023 08:00AM New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis  
Apr 16, 2023 04:00AM Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
Mar 29, 2023 05:59PM Form X-17A-5 FIRST ANALYSIS SECURITIE For: Dec 31
Mar 28, 2023 08:00AM Yunu Opens the Yunuverse, Increasing Trial Access for Patients and Solving Staffing Challenges for Cancer Centers, Pharma, and CRO Customers
Mar 9, 2023 08:00AM Nirvana Healthcare Ventures Builds World-Class Team to Support Midwest Innovation
Mar 8, 2023 08:32AM RenovoRx (RNXT) Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic
Mar 8, 2023 08:30AM RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
Mar 2, 2023 08:30AM RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
Feb 28, 2023 04:05PM Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results
Feb 20, 2023 03:40PM PROVINCES IN CHINA AND UNITED STATES LEAD GLOBAL RANKING FOR RISK FROM CLIMATE CHANGE AND EXTREME WEATHER
Feb 13, 2023 04:01PM The Fenway Institute and NORC - Older LGBT+ Adults Have Higher Rates of Kidney Disease than Heterosexual Peers
Feb 2, 2023 05:48PM Bespoke Partners Posts Massive Growth, Hits Key Milestones
Jan 11, 2023 02:12PM COPILOT Receives New Strategic Investment from QHP Capital
Jan 10, 2023 06:30AM QHP Capital Invests in COPILOT
Dec 15, 2022 07:35AM New Analysis Finds 30% of Chemical Safety Data Sheets Tested Include Inaccurate Hazard Warnings, Put Workers at Risk
Dec 15, 2022 07:35AM New Analysis Finds 30% of Chemical Safety Data Sheets Tested Include Inaccurate Hazard Warnings, Put Workers at Risk
Dec 10, 2022 10:00AM Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hemato
Nov 12, 2022 04:30PM Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022
Nov 8, 2022 07:00AM Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 3, 2022 02:31PM New Study Finds Higher Prevalence of Age-Related Macular Degeneration (AMD) Cases than Previously Determined and a High Degree of County Variation
Nov 3, 2022 09:40AM Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual
Nov 3, 2022 07:30AM Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
Nov 3, 2022 06:31AM Profound Improvement for Pancreatic Cancer Patients Using CivaSheet®, a New Radiation Device
Nov 1, 2022 07:00AM Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
Oct 27, 2022 09:00AM Drive My Way Closes $4.4 Million Series A Financing Round
Oct 24, 2022 08:00AM Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic
Oct 24, 2022 07:04AM Castle Biosciences Inc. (CSTL) Presents New Data Demonstrating Impact of DecisionDx-SCC Test Results on Management of Medicare-Eligible Patients with cSCC and One or More Risk Factors
Oct 24, 2022 07:00AM Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Ri
Oct 19, 2022 07:00AM Premia Spine’s TOPS™ Facet Replacement Demonstrates Significant Improvement in All Patient-Reported Outcome Measures in FDA Trial
Oct 13, 2022 11:38PM CoolR Group raises $10 million to accelerate automated ordering globally
Sep 27, 2022 09:00AM Truveta Announces Collaboration with Boston Scientific to Advance Post-Procedure Patient Insights and Help Address Healthcare Disparities
Sep 27, 2022 09:00AM Truveta Announces Collaboration with Boston Scientific to Advance Post-Procedure Patient Insights and Help Address Healthcare Disparities
Sep 22, 2022 12:53PM OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results
Sep 16, 2022 07:02AM Intellia Therapeutics (NTLA) Reports Positive Interim Data for NTLA-2002
Sep 16, 2022 07:00AM Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
Sep 7, 2022 06:30PM Gilead's Trodelvy extends breast cancer survival by 3.2 months -study
Sep 5, 2022 01:30AM OSE Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer after Failure to Immune Checkpoint Inhibitors at ESMO Congress 2
Aug 27, 2022 10:59AM New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
Aug 2, 2022 08:00AM Mycovia Pharmaceuticals Announces Presentation of Topline Results from Two Studies Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC) at the 2022
Jul 27, 2022 02:16PM Payment Integrity Leader ClaimLogiq Acquires NLP Pioneer SyTrue
Jul 22, 2022 08:36AM EdgeIQ Raises $8.5 Million to Fuel Its Mission of Growing the Connected Product Economy
Jun 24, 2022 05:52AM Mirum Pharmaceuticals (MIRM) Reports New Data at The International Liver Congress of the European Association for the Study of the Liver
Jun 24, 2022 03:00AM Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
View More Recent Stories View Older Stories